SCHEMBL22734504

SCHEMBL22734504

CCn1cnc2c1C(=O)NC(O)N2Cc1ccc(CNC(=O)C(NC(=O)OC(C)(C)C)c2ccc(C)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ KMT2A Q03164 1/20 0.33
▸ F2 P00734 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ PRSS1 P07477 1/20 0.33
▸ HTRA1 Q92743 3/20 0.32
▸ S1PR3 Q99500 1/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ TP53 P04637 1/20 0.31
▸ PPARG P37231 1/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22735702 0.86 CTSK (0.38) CTSSCTSKCYP3A4ALDH1A1LMNA
SCHEMBL22735938 0.86 CTSK (0.38) CTSSCTSKCYP3A4ALDH1A1LMNA
SCHEMBL22734659 0.85 KMT2A (0.37) KMT2ACYP3A4CYP1A2CYP2C19RECQL
SCHEMBL22734497 0.77 BRD4 (0.56) —
SCHEMBL22734583 0.76 KMT2A (0.38) KMT2AALDH1A1LMNA
SCHEMBL22734477 0.73 TP53 (0.36) KMT2AALDH1A1LMNAPOLBTP53
SCHEMBL22735698 0.70 KMT2A (0.38) KMT2ACYP3A4ALDH1A1TP53
SCHEMBL22735677 0.70 KMT2A (0.36) KMT2AALDH1A1LMNATP53
SCHEMBL11481763 0.68 CTSS (0.57) CTSSCTSK
SCHEMBL29527526 0.66 CTSS (0.73) CTSSCTSKKMT2AF2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180510-B2 Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-11-23 — — US disclosed
US-20200377522-A1 XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377522-A1 XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS BET1, BRD4, BRD3 CTSS 3787/4885CTSK 4064/4885KMT2A 941/4885
US-11180510-B2 Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins BET1, BRD4, BRD3 CTSS 3770/4885CTSK 4110/4885KMT2A 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback